The drug Sacituzumab govitecan-hziy is recommended by healthcare professionals to treat metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. This drug is sold under the brand name Trodelvy. Trodelvy single-dose vials are supplied in 180 mg and 200 mg to administer intravenously. https://www.indianpharmanetwork.in/triple-negative-breast-cancer-and-their-treatment/